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Background: Slowing of the electroencephalogram (EEG) is frequent in Parkinson’s (PD)
and Alzheimer’s disease (AD) and correlates with cognitive decline. As overlap pathology
plays a role in the pathogenesis of dementia, it is likely that demented patients in PD show
similar physiological alterations as in AD.
Objective:To analyze distinctive quantitative EEG characteristics in early cognitive dysfunc-
tion in PD and AD.
Methods: Forty patients (20 PD- and 20 AD patients with early cognitive impairment) and
20 normal controls (NC) were matched for gender, age, and education. Resting state EEG
was recorded from 256 electrodes. Relative power spectra, median frequency (4–14 Hz),
and neuropsychological outcome were compared between groups.
Results: Relative theta power in left temporal region and median frequency separated the
three groups significantly (p=0.002 and p<0.001). Relative theta power was increased
and median frequency reduced in patients with both diseases compared to NC. Median
frequency was higher in AD than in PD and classified groups significantly (p=0.02).
Conclusion: Increase of theta power in the left temporal region and a reduction of median
frequency were associated with presence of AD or PD. PD patients are characterized by a
pronounced slowing as compared to AD patients.Therefore, in both disorders EEG slowing
might be a useful biomarker for beginning cognitive decline.
Keywords: Parkinson’s disease,Alzheimer’s disease, mild cognitive impairment, dementia, quantitative electroen-
cephalography, neuropsychology
INTRODUCTION
Mild cognitive impairment (MCI) is a prodromal syndrome of
neurodegenerative dementia without significant impairment in
activities of daily living (ADL); however, it is unspecific as it can
be caused by various pathologies (Winblad et al., 2004), and a con-
siderable part of MCI patients remain stable or improve over time
(Ritchie et al., 2001). Diagnostic criteria for MCI due to Parkin-
son’s disease (PD-MCI) and Alzheimer’s disease (AD-MCI) were
established (Albert et al., 2011; Litvan et al., 2012). The progression
rate in PD-MCI to PD dementia (PDD) is approximately 60% over
4 years (Janvin et al., 2006); the rate of conversion to AD in MCI
patients varies depending on study design and definition of MCI,
though maximally one to two fifths of MCI patients with amnestic
impairments at baseline progress to dementia within 2–3 years of
follow-up (Schmidtke and Hermeneit, 2008; Duara et al., 2011).
However, novel treatment strategies require initiation of treatment
at the earliest possible time (Panza et al., 2012), and, therefore, the
corroboration of the diagnosis and the identification of the cause
of MCI is very important.
Quantitative electroencephalography (qEEG) has increasingly
been used to characterize cognitive impairment in different dis-
orders (Fonseca et al., 2009; Roh et al., 2011). The eyes closed
resting state qEEG of patients suffering from dementia due to
AD is characterized by a shift to lower frequencies (Penttilä et al.,
1985; Duffy et al., 1995; Bennys et al., 2001; Czigler et al., 2008).
The same observation is reported in PD patients with cognitive
decline (Caviness et al., 2007; Fonseca et al., 2009; Bousleiman
et al., 2014). In contrast to AD, slowing of electroencephalo-
gram (EEG) can already be found in de novo PD patients with-
out any cognitive deficits (Stoffers et al., 2007). Comparison of
AD and PDD patients with a similar degree of overt demen-
tia showed more pronounced EEG slowing in PDD (Babiloni
et al., 2011; Fonseca et al., 2013). However, it is unknown whether
qEEG measures reliably discriminate between the two diseases at
the beginning of the dementing process or whether they sim-
ply correlate with the extent of cognitive decline. Thus, the
present study aims at characterizing qEEG parameters in PD-MCI
and AD-MCI.
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MATERIALS AND METHODS
PATIENTS
Twenty patients with PD and cognitive decline (see Table 1) were
recruited from the outpatient clinic for movement disorders of the
University Hospital of Basel. PD was diagnosed according to UK
Parkinson’s disease brain bank criteria. The diagnosis of PD-MCI
(N = 15) was based on Litvan et al. (2012). Diagnosis of “probable
PDD” (N = 5) was made according to Emre et al. (2007), p. 007.
All PD patients were treated with dopaminergic drugs [median
levodopa-equivalent dose (LED)= 829 mg; range 188–3044 mg].
Thirty-seven outpatients (Table 1) with either amnestic MCI
(AD-MCI,N = 12) or mild dementia due to probable AD (N = 8)
were recruited from the Memory Clinic, University Center for
Medicine of Aging, Basel. Thereof 20 patients were matched to the
PD group for gender, age, and education. MCI due to probable
AD was diagnosed according to Winblad et al. (2004). Dementia
due to probable AD was diagnosed according to McKhann et al.
(1984).
Exclusion criteria consisted of MMSE score (Folstein et al.,
1975) <24/30, significant psychiatric or organic brain disorders
other than PD or AD, any other severe illness, and drug treatment
influencing EEG recordings (antiepileptic or antipsychotic drugs).
Twenty normal controls (NC) were matched to both patient
groups according to gender, age, and education (Table 1). Inclu-
sion criteria were a subjective report of good health and a neu-
ropsychological examination within normal limits. Exclusion cri-
teria were a past and/or current diagnosis of any major brain dis-
order, alcoholism, psychiatric disorder, general anesthesia within
the last 3 months and cognitive problems. To compare global
cognitive function between both patient groups, we chose a com-
bination of the MMSE and the clock drawing test (CDT) (Thal-
mann et al., 2002). The study protocol was approved by the local
ethics committee. Written informed consent was provided by all
participants.
NEUROPSYCHOLOGY
Patients were examined with a comprehensive battery of neuropsy-
chological tests [see Hatz et al. (2013) for details]. Raw scores of
tests were transformed into demographically (age, gender, and
education) adjusted z-scores (Berres et al., 2000). Cognitive per-
formance was judged to be impaired when z-scores were less than
−1.28, i.e., below the 10th percentile.
EEG RECORDING
Electroencephalogram was recorded with a 256-channel EEG Sys-
tem (Netstation 300, EGI, Inc., Eugene, OR 97403, USA; DC-
amplifier; sampling rate: 1000 Hz; high-pass filter: 0.01 Hz; vertex-
reference, impedance≤40 kΩ). They were instructed to relax, but
to stay awake and to minimize eye and body movements. A con-
tinuous EEG with closed eyes was recorded for 12 min. During
data acquisition, a subset of electrodes was monitored online
by a technician to check for vigilance and artifacts. For patients
taking benzodiazepines for sleep deprivation (one patient per
group), medication was discontinued before EEG recording for at
least 48 h. Only benzodiazepines with short half-life were allowed.
One patient of the PD group was taking low-dose quetiapine for
sleep deprivation, three patients were taking acetylcholinesterase
inhibitors.
PROCESSING OF EEG DATA
Two minutes of EEG data (single segments of at least 40 s) without
artifacts or signs of sleep and drowsiness were visually selected,
filtered (0.5–70 Hz, 2400 order least-squares filter) and down-
sampled (500 Hz). Data from 214 electrodes (excluding cheek and
neck electrodes) were subjected to automated artifact detection
(Hatz et al., 2014). Resulting EEG data were re-referenced to aver-
age reference and bad channels were interpolated with the spher-
ical spline method. Power spectra were calculated from epochs of
4 s duration (Welch’s method, spectral resolution 0.25 Hz) using
Table 1 | Demographic characteristics and medications.
NC ADa PDa p-Valuea Sub-group comparisonsb
Age (years) 73.5 (67–83) 73.5 (57–87) 74 (60–84) 0.77
Education (years) 13.5 (10–19) 14 (8–20) 15.5 (8–20) 0.60
Gender (F/M) 11/9 10/10 5/15 0.12
MMSE 29 (28–30) 28 (24–30) 29 (24–30) 0.02* NC>AD*, NC>PD*, AD=PD
MMSE and CDT 9 (7–9) 9 (5–9) 8.5 (4–9) 0.34
l-DOPA – – 18/20
DOPA-agonists – – 13/20
MAO-inhibitors – – 6/20
Amantadine – – 2/20
COMT-inhibitor – – 2/20
AChE-inhibitors – 1/20 2/20
Antidepressants – 3/20 4/20
Neuroleptics – – 1/20
Benzodiazepines 1/20 1/20 1/20
ap-Values for ANOVA, Kruskal–Wallis test.
bMann–Whitney U test.
*p<0.05, “=” no significant difference.
Frontiers in Aging Neuroscience www.frontiersin.org November 2014 | Volume 6 | Article 314 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Benz et al. qEEG in Parkinson’s and Alzheimer’s disease
a 80% Hanning window. The relative power for each frequency
band was computed as the ratio between the absolute band-
power and the bandpower from 1 to 30 Hz. Relative power in
the delta- (1–4 Hz), theta- (4–8 Hz), alpha1- (8–10 Hz), alpha2-
(10–13 Hz), and beta- (13–30 Hz) bands were logit-transformed
[t (x)= log(x/(1− x)] to achieve an approximate normal distri-
bution (Gasser et al., 1982). Global band powers (average over
all 214 electrodes) and regional band powers were computed. For
regional analyses, electrodes were grouped into 10 regions of inter-
est (ROI) corresponding to the frontal, central, temporal, parietal,
and occipital areas bilaterally (Stoffers et al., 2007). Median fre-
quency was calculated in a spectral window between 4 and 14 Hz
at occipital electrodes. For calculation of the median frequency, a
“center of gravity” approach was chosen, taking into account all
spectra generated for a single subject.
STATISTICS
Demographic characteristics were compared between groups
using non-parametric tests. EEG variables and results of neu-
ropsychological tests were compared between the three groups
using ANOVA. Subsequently, post hoc t -tests between sub-groups
were applied. In case of regional EEG power analysis, permu-
tation tests (statistics: ANOVA, t -test, number of 10,000 per-
mutations) were used (Nichols and Holmes, 2002). A logistic
regression analysis with backwards elimination to classify both
groups was performed using the significant EEG measures from
permutation tests as independent variables. Age, education, and
gender served as covariates. Subsequently, a receiver–operator-
characteristic (ROC) analysis was performed. Results with p-
values <0.05 were considered significant. Comparison of demo-
graphic characteristics, global relative band power, neuropsycho-
logical results between groups and regression, as well as ROC
analysis were done using R®. Frequency analysis, ANOVA’s, t -tests,
and permutation tests were performed with Matlab®.
RESULTS
DEMOGRAPHICS
No significant differences between the patient groups regarding
age, education, the combined MMSE/CDT, and gender were found
(Kruskal–Wallis test, see Table 1). MMSE scores of both patient
groups were similar and significantly smaller than those of the NC
group (p= 0.04).
NEUROPSYCHOLOGY
Table 2 gives results of group- and sub-group comparisons. Sub-
group comparison found differences between PD and AD patients
in alertness/reaction time and divided attention/errors and in
verbal memory (encoding, recall, and recognition).
QUANTITATIVE EEG
Global relative theta and global relative alpha2 power differed
between the three groups. In sub-group comparison, NC had lower
theta power compared PD and tended to lower theta power com-
pared to AD. AD tended to have lower global theta with respect to
PD, which had lower power in the alpha2 band compared to NC.
Detailed results are given in Table 3.
Regional analysis of relative power data revealed group and
sub-group differences in the theta- and alpha2 bands as depicted
in Figure 1. In both patient groups, the most significant differences
as compared to NC were found in the left temporal region.
Occipital median frequency differed significantly between
groups with the following pattern found in the post hoc analy-
sis: NC>AD (p< 0.05), NC>PD (p< 0.001), and AD>PD
(p< 0.05).
Table 2 | Results of the neuropsychological assessments [age-, gender, and education corrected z-values (Berres et al., 2000)].
NC ADa PDa p-Valuea Sub-group comparisonsb
Alertness −0.2 (−1.8 to 0.7) −0.3 (−1.8 to 2.3) 0.1 (−2.1 to 2.1) 0.14
Alertness RT 0.3 (−1.5 to 2.3) −0.1 (−2.3 to 2.8) −1.1 (−2.1 to 0.5) 0.004 NC=AD, NC>PD***, AD>PD*
Divided attention: errors 0.2 (−1.9 to 2.3) 0.2 (−1.2 to 2.3) −1.5 (−2.1 to 2.3) 0.01 NC=AD, NC>PD*, AD>PD**
TMT-A 0.4 (−1.3 to 3.5) 0 (−2.6 to 3.5) −0.3 (−3 to 1.1) 0.06
Corsi blocks fw 0 (−1.2 to 1.2) 0 (−1.5 to 1.8) −0.6 (−1.8 to 1.2) 0.32
Digit span fw 0.1 (−2.9 to 1.8) −0.5 (−2 to 2.1) 0.2 (−1.1 to 3) 0.10
Corsi blocks bw 0.5 (−0.8 to 1.9) −0.4 (−3.5 to 1.2) −0.1 (−2.1 to 1.5) 0.01 NC>AD**, NC=PD, AD=PD
Digit span bw 0.3 (−1.7 to 2.3) −0.5 (−1.7 to 2.9) 0 (−1.1 to 2.3) 0.41
Figures fluency −0.1 (−2 to 2) −1 (−3.7 to 0.7) −0.8 (−1.9 to 1.2) 0.01 NC>AD**, NC>PD*, AD=PD
Phonemic fluency 0 (−1.1 to 2.6) −0.4 (−2.7 to 1.2) −0.2 (−3.3 to 2) 0.23
Semantic fluency 0.3 (−2.3 to 2) −0.9 (−2.5 to 0.7) −0.5 (−1.8 to 0.8) 0.002 NC>AD**, NC>PD*, AD=PD
Boston naming test −0.4 (−1.9 to 1.7) −0.4 (−2.3 to 1.3) −0.6 (−3.3 to 1.3) 0.20
Encoding −0.1 (−1.7 to 1.8) −2 (−3.8 to −0.7) −1.3 (−3.7 to 0.2) <0.001 NC>AD***, NC>PD***, PD>AD**
Recall 0.3 (−2.1 to 1.4) −2.5 (−4 to −0.3) −1.3 (−3.3 to 0.4) <0.001 NC>AD***, NC>PD**, PD>AD**
Recognition 0.2 (−2.4 to 1.7) −1.6 (−4.5 to 1.7) −0.6 (−3 to 1.6) <0.001 NC>AD***, PD>AD**, NC=PD
ap-Values for Kruskal–Wallis test.
bp-Values for Mann–Whitney U test.
*p<0.05, **p<0.01, ***p<0.001, “=” no significant difference.
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Table 3 | Global relative power and median frequencies (median and range).
NC ADa PDa p-valuea Sub-group comparisonsb
Delta (1–4 Hz) 19.5 (6.1–40.7) 19.4 (7.5–32.9) 20.4 (7.6–37.0) 0.59
Theta (4–8 Hz) 11.2 (5.7–61.6) 16.5 (6.5–46.9) 24.4 (9.4–56.6) 0.002 NC<AD#, NC<PD**, AD<PD*
Alpha1 (8–10 Hz) 13.7 (5.8–56.2) 25.7 (5.5–55.4) 16.9 (6.1–37.0) 0.39
Alpha2 (10–13 Hz) 14.2 (2.7–56.1) 11.8 (4.4–36.2) 9.3 (4.1–25) 0.04 NC>PD**, AD=NC, AD=PD
Beta (13–30 Hz) 24.2 (11.4–42.1) 18.9 (7.5–48.2) 22.3 (8.8–28.3) 0.30
Median frequency 9.2 (8.1–10.4) 8.8 (7.1–10.5) 8.1 (6.9–9.4) <0.001 NC>AD*, NC>PD***, AD>PD*
ap-Values for ANOVA.
bp-Values for t-tests.
#p<0.1, *p<0.05, **p<0.01, ***p<0.001, “=” no significant difference.
FIGURE 1 | Differences of regional band power between the three groups (NC,AD, and PD). (A) Relative theta power, (B) relative alpha2 power. (First
column: ANOVA, second to forth columns: t -tests; pink: p≤0.05; red: p≤0.01; corrected for multiple comparison by permutation).
As the median frequency was significantly different between AD
and PD, it was chosen as independent variable for a logistic regres-
sion model to classify the two groups. A significant classification of
both groups (p= 0.02) was achieved. After backwards elimination,
the resulting model included only median frequency as predictor
(p= 0.03). ROC analysis yielded an AUC of 0.72 with a sensitivity
and specificity at the best index of Youden (0.45) of 60 and 85%,
respectively. The positive predictive and negative predictive values
were 80 and 68%, respectively.
CONTROL ANALYSIS
We checked for a confounding influence of the variables MMSE,
LED, alertness, age, and gender on the power values, by entering
the variables into linear models with stepwise backwards elimina-
tion. No significant effects of the potentially confounding variables
on the qEEG parameters were found. We conducted sensitivity
analysis by running the statistics on all but one PD patient taking
neuroleptics and on all but three patients taking AChE-inhibitors.
The outcome was not affected as similar results and significances
were obtained with and without those patients.
DISCUSSION
The main alteration of EEG in patients with subtle cognitive
deficits due to AD or PD consists in an increase of relative theta
power, predominantly in the temporal regions and in a slowing of
the occipital median frequency. The slowing is more pronounced
in PD than in AD patients.
Bi-temporal increase of relative theta power in demented PD
and AD patients is a known finding (Babiloni et al., 2011). While in
PD, EEG slowing occurs already before cognitive decline (Berendse
and Stam, 2007), it is observed in AD with incipient MCI (Roh
et al., 2011).
Dysfunction of the cholinergic system is common in both, AD
and PD (Mesulam et al., 2004; Bohnen and Albin, 2011) and an
overlap of histopathological (Hughes et al., 1993; Emre, 2003)
and biochemical changes (Alves et al., 2014) is known. EEG fre-
quency is accelerated by cholinergic function and responds to
therapy with acetylcholinesterase inhibitors in AD und PD (Fogel-
son et al., 2003; Babiloni et al., 2013). This fact could explain
partly the slowing of EEG in both patient groups in our sam-
ple. Interestingly, EEG slowing is more pronounced in PD than in
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AD in the present study. This is in line and extends the findings
by Babiloni et al. who found similar results AD and PD patients
with more advanced cognitive dysfunction This difference may
reflect a greater cholinergic deficit in cognitively impaired patients
with PD-compared to AD (Bohnen et al., 2003; Kotagal et al.,
2012) and reflects the degeneration of the cholinergic system
as an important factor for cognitive decline in PD (Emre et al.,
2004).
The advantage of the present study is the comparison of
demographically well balanced groups of patients with AD or
PD at incipient cognitive decline with a group of NCs. Limi-
tations include the relatively small sample sizes and the inher-
ent failure of AD-MCI patients to formally fulfill the diagnos-
tic criteria of AD. Longitudinal assessment of these patients is
warranted.
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